Table 2.
Changes in mean and maximum CCA-IMT values between baseline and follow-up
| Cilostazol (n = 101) | Control (n = 107) | Cronbach’s alpha | ICC | p value | |||
|---|---|---|---|---|---|---|---|
| Left maximum CCA-IMT | 0.001 | ||||||
| Baseline | 1.105 | ±0.382 | 1.101 | ±0.410 | 0.929 | 0.833 | |
| Follow-up | 1.057 | ±0.396 | 1.122 | ±0.447 | 0.961 | 0.909 | |
| Mean change | –0.048 | ±0.186 | 0.022 | ±0.163 | |||
| Left mean CCA-IMT | <0.001 | ||||||
| Baseline | 0.863 | ±0.232 | 0.855 | ±0.242 | 0.934 | 0.851 | |
| Follow-up | 0.810 | ±0.220 | 0.879 | ±0.278 | 0.958 | 0.912 | |
| Mean change | –0.052 | ±0.102 | 0.023 | ±0.112 | |||
| Right maximum CCA-IMT | 0.001 | ||||||
| Baseline | 1.005 | ±0.348 | 1.053 | ±0.405 | 0.919 | 0.815 | |
| Follow-up | 0.968 | ±0.313 | 1.103 | ±0.489 | 0.923 | 0.840 | |
| Mean change | –0.037 | ±0.173 | 0.050 | ±0.200 | |||
| Right mean CCA-IMT | <0.001 | ||||||
| Baseline | 0.801 | ±0.206 | 0.822 | ±0.229 | 0.912 | 0.812 | |
| Follow-up | 0.764 | ±0.183 | 0.865 | ±0.287 | 0.940 | 0.877 | |
| Mean change | –0.038 | ±0.106 | 0.042 | ±0.139 | |||
Values are mean ± SD. Comparisons of IMTs during treatment with baseline values were performed by ANCOVA adjusted for age, sex, stroke subtype, location, previous stroke, hypertension, diabetes, hyperlipidemia, current smoking, statin, body mass index, glycated hemoglobin, total cholesterol, HDL cholesterol, triglyceride, LDL cholesterol, and interval
ICC intraclass correlation coefficient